Diagnostics
Genomics

Myriad Genetics sells prenatal testing unit to Labcorp for $210m

Myriad Genetics is divesting its four-brand prenatal testing portfolio to Labcorp as it refocuses strategy on oncology and cancer care.
Myriad Genetics is divesting its four-brand prenatal testing portfolio to Labcorp as it refocuses strategy on oncology and cancer care.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Ascentage Pharma's lisaftoclax wins China BTD for first-line CLL/SLL

China's NMPA has granted lisaftoclax Breakthrough Therapy Designation in combination with acalabrutinib for treatment-naïve CLL/SLL patients.
China's NMPA has granted lisaftoclax Breakthrough Therapy Designation in combination with acalabrutinib for treatment-naïve CLL/SLL patients.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

AltruBio Phase 2a UC data show dose-response signal for ALTB-268

AltruBio presented ASCEND UC2a results at UEG Week 2026, showing 23.1% remission in its higher-dose cohort of therapy-refractory ulcerative colitis patients.
AltruBio presented ASCEND UC2a results at UEG Week 2026, showing 23.1% remission in its higher-dose cohort of therapy-refractory ulcerative colitis patients.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Optimi Health completes MDMA batch for Phase 3 PTSD trial and export

Optimi Health has manufactured MDMA supplies for a Canadian Phase 3 trial, an Israel MAPS study, and commercial export to Australia before year-end.
Optimi Health has manufactured MDMA supplies for a Canadian Phase 3 trial, an Israel MAPS study, and commercial export to Australia before year-end.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Diagnostics
Cell & Gene Therapy

Telix Pharmaceuticals posts $245m Q3 revenue, closes ITM merger

Telix reported 19% year-on-year revenue growth in Q3 2026 and confirmed its $1.65bn merger with isotope supplier ITM, targeting over $1bn in
Telix reported 19% year-on-year revenue growth in Q3 2026 and confirmed its $1.65bn merger with isotope supplier ITM, targeting over $1bn in
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Medicovestor wins FDA Fast Track for ADC MC001 in pancreatic cancer

The New York biotech said the designation will support faster regulatory review of its FRα-targeting chemoimmunotherapy ADC ahead of a Phase 1 trial.
The New York biotech said the designation will support faster regulatory review of its FRα-targeting chemoimmunotherapy ADC ahead of a Phase 1 trial.
The Biotech Times Editorial Team  · 
Biologics
Diagnostics

ITM radiopharmaceutical dose-response data backs ITM-11 in GEP-NETs

Phase 3 COMPETE trial data show objective response rates rising from 12% to 64% across tumour dose quartiles for 177Lu-edotreotide in neuroendocrine tumours.
Phase 3 COMPETE trial data show objective response rates rising from 12% to 64% across tumour dose quartiles for 177Lu-edotreotide in neuroendocrine tumours.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

F2G olorofim matches AmBisome in Phase 3 invasive aspergillosis trial

Phase 3 OASIS data show oral olorofim non-inferior to IV AmBisome on 42-day mortality, with a markedly better renal safety profile.
Phase 3 OASIS data show oral olorofim non-inferior to IV AmBisome on 42-day mortality, with a markedly better renal safety profile.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Gesynta Pharma completes NOVA trial enrolment ahead of schedule

The Stockholm biotech randomised 213 patients, exceeding its 190-person target by three months, with topline data from its non-hormonal endometriosis candidate due Q2
The Stockholm biotech randomised 213 patients, exceeding its 190-person target by three months, with topline data from its non-hormonal endometriosis candidate due Q2
The Biotech Times Editorial Team  · 
Diagnostics
Digital Health
Medical Devices

Circle CVI joins EXIT-CVD consortium to advance AI cardiac imaging

Circle CVI joins a 42-partner, EUR 27.6m European consortium running 22 cardiovascular studies across 17 countries, contributing its AI imaging platform.
Circle CVI joins a 42-partner, EUR 27.6m European consortium running 22 cardiovascular studies across 17 countries, contributing its AI imaging platform.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Duvakitug Phase 2b data show durable IBD remission at 44 weeks

Teva and Sanofi's TL1A antibody maintained clinical remission and endoscopic improvement in both ulcerative colitis and Crohn's disease through 44 weeks of maintenance
Teva and Sanofi's TL1A antibody maintained clinical remission and endoscopic improvement in both ulcerative colitis and Crohn's disease through 44 weeks of maintenance
The Biotech Times Editorial Team  · 
Biologics
Cell & Gene Therapy
Regulatory Science

PolarityBio SkinTE Phase 3 trial wins top SAWC abstract award

PolarityBio's pivotal COVER DFUS II trial met its primary endpoint and earned the highest-scoring abstract in clinical research at SAWC Fall 2026.
PolarityBio's pivotal COVER DFUS II trial met its primary endpoint and earned the highest-scoring abstract in clinical research at SAWC Fall 2026.
The Biotech Times Editorial Team  · 
Subscribe to